Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report
Manaka Sato, Riku Takemura, Masahiro Yuki, Tomoya Saika, Michiko Yamazaki, Tsutomu Yamazaki, Masaya Sakamoto · 2026
Read Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report by Manaka Sato, Riku Takemura, Masahiro Yuki, Tomoya Saika, Michiko Yamazaki, Tsutomu Yamazaki, Masaya Sakamoto (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13278717.txt.
Description
Manaka Sato and co-authors survey diabetes drug prescribing in older Japanese patients in a 2026 preliminary report. Japan's geriatrics society added GLP-1 class drugs to its caution list in its 2025 guidance. The study describes how often these drugs appear alongside other caution-listed glucose-lowering medicines.
Records covered 214 outpatients aged sixty-five or older treated in late 2025 at one centre. About a quarter received a GLP-1 drug, and most of those patients had obesity. Users took more than three glucose-lowering drugs on average, often including metformin, SGLT2 inhibitors, sulfonylureas, or insulin. Among the oldest group, oral semaglutide and dulaglutide were prescribed most. The authors flag complex regimens needing careful oversight.
Catalog record
| CREATOR | Manaka Sato, Riku Takemura, Masahiro Yuki, Tomoya Saika, Michiko Yamazaki, Tsutomu Yamazaki, Masaya Sakamoto |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |